Illumina Stock Extends A 5-Day Losing Streak To A 10% Loss
Shares of Illumina (ILMN) have closed lower in each of the last 5 sessions, a cumulative decline of 10.3%. That erased about $3.4 billion from the company’s market value, which now stands at about $29.9 billion. The stock closed at $198.00 on Monday, November 16, 32.6% below its 52-week high of $293.69 and 73.0% above its low of $114.44.

How The Streak Stacks Up Against The S&P 500
Returns for ILMN and the S&P 500 over the streak and the periods around it, all ending Monday, November 16 and including dividends:
| Return Period | ILMN | S&P 500 |
|---|---|---|
| 1 Day | -4.4% | -1.9% |
| 5 Days (Current Streak) | -10.3% | -1.7% |
| 1 Month (21 Trading Days) | -24.6% | -3.1% |
| 3 Months (63 Trading Days) | 5.2% | -3.3% |
| Year To Date | 51.0% | 9.4% |
| 1 Year (252 Trading Days) | 65.1% | 11.4% |
How The Streak Compares With The Market
Over the same 5 trading days, the S&P 500 returned -1.7% including dividends, so the slide is mostly Illumina’s own story rather than the market’s. 16 other S&P 500 stocks are currently on losing streaks of 5 days or longer. Over the past three months the stock is up 5.2%, a window that includes the streak; over the other 58 sessions of that window it was up 17.3%.
Do The Fundamentals Justify The Selling?
On the fundamentals, revenue grew 5.8% over the last twelve months, against a median of 7.9% for S&P 500 Health Care stocks; its operating margin is 21.4%, versus a median of 17.4%; and the stock trades at 33.4 times trailing earnings against a median of 31.1. The read is mixed: margins above the median on one side, revenue growth below the median on the other.
If the drop has you weighing an entry, resist buying on price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still hold up.
Falling Prices Test Conviction. Rules Do Not Flinch
A losing streak forces a choice on every holder: sell into weakness, average down, or freeze. All three are emotional answers to what should be an analytical question, and decisions made that way tend to be expensive ones.
The Trefis High Quality (HQ) Portfolio takes the emotion out: about 30 quality businesses screened for the fundamentals that survive bad stretches, held and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Let the rules decide, not the tape.